1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Orphan Drugs Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Oncology
1.2.3 Pulmonary
1.2.4 Neurology
1.2.5 Hematology
1.2.6 Endocrinology
1.2.7 Cardio-vascular
1.2.8 Metabolic Disorders
1.2.9 Others
1.3 Market by End Users
1.3.1 Global Orphan Drugs Market Share by End Users: 2017 VS 2021 VS 2028
1.3.2 Baby and Child
1.3.3 Teenager
1.3.4 Adult
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Orphan Drugs Market Perspective (2017-2028)
2.2 Orphan Drugs Growth Trends by Region
2.2.1 Orphan Drugs Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Orphan Drugs Historic Market Size by Region (2017-2022)
2.2.3 Orphan Drugs Forecasted Market Size by Region (2023-2028)
2.3 Orphan Drugs Market Dynamics
2.3.1 Orphan Drugs Industry Trends
2.3.2 Orphan Drugs Market Drivers
2.3.3 Orphan Drugs Market Challenges
2.3.4 Orphan Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Orphan Drugs Players by Revenue
3.1.1 Global Top Orphan Drugs Players by Revenue (2017-2022)
3.1.2 Global Orphan Drugs Revenue Market Share by Players (2017-2022)
3.2 Global Orphan Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Orphan Drugs Revenue
3.4 Global Orphan Drugs Market Concentration Ratio
3.4.1 Global Orphan Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Orphan Drugs Revenue in 2021
3.5 Orphan Drugs Key Players Head office and Area Served
3.6 Key Players Orphan Drugs Product Solution and Service
3.7 Date of Enter into Orphan Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Orphan Drugs Breakdown Data by Type
4.1 Global Orphan Drugs Historic Market Size by Type (2017-2022)
4.2 Global Orphan Drugs Forecasted Market Size by Type (2023-2028)
5 Orphan Drugs Breakdown Data by End Users
5.1 Global Orphan Drugs Historic Market Size by End Users (2017-2022)
5.2 Global Orphan Drugs Forecasted Market Size by End Users (2023-2028)
6 North America
6.1 North America Orphan Drugs Market Size (2017-2028)
6.2 North America Orphan Drugs Market Size by Country (2017-2022)
6.3 North America Orphan Drugs Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Orphan Drugs Market Size (2017-2028)
7.2 Europe Orphan Drugs Market Size by Country (2017-2022)
7.3 Europe Orphan Drugs Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Orphan Drugs Market Size (2017-2028)
8.2 Asia-Pacific Orphan Drugs Market Size by Country (2017-2022)
8.3 Asia-Pacific Orphan Drugs Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Orphan Drugs Market Size (2017-2028)
9.2 Latin America Orphan Drugs Market Size by Country (2017-2022)
9.3 Latin America Orphan Drugs Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Orphan Drugs Market Size (2017-2028)
10.2 Middle East & Africa Orphan Drugs Market Size by Country (2017-2022)
10.3 Middle East & Africa Orphan Drugs Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Detail
11.1.2 Bristol-Myers Squibb Business Overview
11.1.3 Bristol-Myers Squibb Orphan Drugs Introduction
11.1.4 Bristol-Myers Squibb Revenue in Orphan Drugs Business (2017-2022)
11.1.5 Bristol-Myers Squibb Recent Development
11.2 Roche
11.2.1 Roche Company Detail
11.2.2 Roche Business Overview
11.2.3 Roche Orphan Drugs Introduction
11.2.4 Roche Revenue in Orphan Drugs Business (2017-2022)
11.2.5 Roche Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Orphan Drugs Introduction
11.3.4 Novartis Revenue in Orphan Drugs Business (2017-2022)
11.3.5 Novartis Recent Development
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Detail
11.4.2 Johnson & Johnson Business Overview
11.4.3 Johnson & Johnson Orphan Drugs Introduction
11.4.4 Johnson & Johnson Revenue in Orphan Drugs Business (2017-2022)
11.4.5 Johnson & Johnson Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Detail
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Orphan Drugs Introduction
11.5.4 Pfizer Revenue in Orphan Drugs Business (2017-2022)
11.5.5 Pfizer Recent Development
11.6 Amgen
11.6.1 Amgen Company Detail
11.6.2 Amgen Business Overview
11.6.3 Amgen Orphan Drugs Introduction
11.6.4 Amgen Revenue in Orphan Drugs Business (2017-2022)
11.6.5 Amgen Recent Development
11.7 Sanofi
11.7.1 Sanofi Company Detail
11.7.2 Sanofi Business Overview
11.7.3 Sanofi Orphan Drugs Introduction
11.7.4 Sanofi Revenue in Orphan Drugs Business (2017-2022)
11.7.5 Sanofi Recent Development
11.8 AstraZeneca
11.8.1 AstraZeneca Company Detail
11.8.2 AstraZeneca Business Overview
11.8.3 AstraZeneca Orphan Drugs Introduction
11.8.4 AstraZeneca Revenue in Orphan Drugs Business (2017-2022)
11.8.5 AstraZeneca Recent Development
11.9 Takeda
11.9.1 Takeda Company Detail
11.9.2 Takeda Business Overview
11.9.3 Takeda Orphan Drugs Introduction
11.9.4 Takeda Revenue in Orphan Drugs Business (2017-2022)
11.9.5 Takeda Recent Development
11.10 Vertex Pharmaceuticals
11.10.1 Vertex Pharmaceuticals Company Detail
11.10.2 Vertex Pharmaceuticals Business Overview
11.10.3 Vertex Pharmaceuticals Orphan Drugs Introduction
11.10.4 Vertex Pharmaceuticals Revenue in Orphan Drugs Business (2017-2022)
11.10.5 Vertex Pharmaceuticals Recent Development
11.11 AbbVie
11.11.1 AbbVie Company Detail
11.11.2 AbbVie Business Overview
11.11.3 AbbVie Orphan Drugs Introduction
11.11.4 AbbVie Revenue in Orphan Drugs Business (2017-2022)
11.11.5 AbbVie Recent Development
11.12 Biogen
11.12.1 Biogen Company Detail
11.12.2 Biogen Business Overview
11.12.3 Biogen Orphan Drugs Introduction
11.12.4 Biogen Revenue in Orphan Drugs Business (2017-2022)
11.12.5 Biogen Recent Development
11.13 Eli Lilly
11.13.1 Eli Lilly Company Detail
11.13.2 Eli Lilly Business Overview
11.13.3 Eli Lilly Orphan Drugs Introduction
11.13.4 Eli Lilly Revenue in Orphan Drugs Business (2017-2022)
11.13.5 Eli Lilly Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
